International Stem Cell Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 10.91, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the International Stem Cell in Jun 30 2026 quarter, has decreased to 33 days, compared to 36 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 18 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 245, from overall ranking in the first quarter 2026 at 1074.

What is Receivable Turnover Ratio?
What is International Stem Cell Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ISCO Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-12.9 %	-7.05 %	-31.66 %	49.26 %	35.93 %
Y / Y Revenue Change	9.32 %	8.74 %	-11.9 %	8.72 %	4.98 %
Receivable Turnover Ratio (TTM)	10.91	10.23	9.86	9.33	9.97
ISCO's Total Ranking	# 245	# 1074	# 215	# 1125	#
Accounts Receivable average collection period days	33	36	37	39	37
Seq. Receivable Change	21.24 %	9.41 %	-28.77 %	-7.81 %	29.38 %
Seq. Revenue Change	15.55 %	7.42 %	-9.03 %	-3.19 %	14.94 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 6
Healthcare Sector	# 19
Overall Market	# 245

Receivable Turnover Ratio Statistics
High	Average	Low
1.88	1.21	0.5
(Jun 30 2026)		(Jun 30 2012)

ISCO Company Profile • Back to ISCO Efficiency Comparisons • Compare ISCO Receivables Turnover Ratio to its Competitors

Financial Statements
International Stem Cell's Accounts Receivable	$ 1 Millions	Visit ISCO's Balance sheet
International Stem Cell's Sales TTM	$ 10 Millions	Visit ISCO's Income Statement
Sources of ISCO's Revenues		Visit ISCO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ISCO's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ISCO's Growth Rates	ISCO's Roa	ISCO's Inventory Turnover Ratio	ISCO's Dividend Comparisons
ISCO's Profitability Ratios	ISCO's Roi	ISCO's Asset Turnover Ratio	ISCO's Dividend Growth
ISCO's Valuation Ratios	ISCO's Roe	ISCO's Financial Strength Ratios	ISCO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Metagenomi Therapeutics Inc	25.05	$ 13.561 Millions	$ 0.541 Millions
Sonida Senior Living Inc	22.59	$ 525.973 Millions	$ 23.283 Millions
U S Physical Therapy Inc	22.40	$ 812.203 Millions	$ 36.251 Millions
Nutriband Inc	22.15	$ 1.618 Millions	$ 0.073 Millions
Ginkgo Bioworks Holdings Inc	20.32	$ 111.863 Millions	$ 5.506 Millions
Lineage Cell Therapeutics Inc	20.02	$ 13.083 Millions	$ 0.654 Millions
Hims and Hers Health Inc	19.65	$ 2,578.494 Millions	$ 131.228 Millions
Lipocine Inc	18.36	$ 1.569 Millions	$ 0.085 Millions
Nrx Pharmaceuticals Inc	17.25	$ 3.394 Millions	$ 0.197 Millions
Polomar Health Services, Inc.	17.19	$ 3.172 Millions	$ 0.185 Millions
Anika Therapeutics Inc	16.70	$ 121.370 Millions	$ 7.266 Millions
Vireo Growth Inc.	16.69	$ 511.706 Millions	$ 30.659 Millions
Neuraxis Inc	15.53	$ 5.316 Millions	$ 0.342 Millions
Agenus Inc	15.44	$ 132.693 Millions	$ 8.595 Millions
Longeveron Inc	15.03	$ 1.187 Millions	$ 0.079 Millions
Medicinova Inc	15.02	$ 0.920 Millions	$ 0.061 Millions
Voyager Therapeutics Inc	14.71	$ 34.459 Millions	$ 2.343 Millions
Halozyme Therapeutics Inc	14.68	$ 1,663.738 Millions	$ 113.332 Millions
Dar Bioscience Inc	14.57	$ 1.345 Millions	$ 0.092 Millions
Nexgel Inc	14.52	$ 11.810 Millions	$ 0.813 Millions
China Pharma Holdings Inc	14.46	$ 3.914 Millions	$ 0.271 Millions
Lftd Partners Inc	14.13	$ 35.335 Millions	$ 2.500 Millions
Talkspace Inc	14.09	$ 246.631 Millions	$ 17.506 Millions
Lifestance Health Group Inc	14.07	$ 1,584.834 Millions	$ 112.665 Millions
Ataibeckley Inc	13.83	$ 4.473 Millions	$ 0.324 Millions
Amneal Pharmaceuticals Inc	13.83	$ 3,117.474 Millions	$ 225.492 Millions
Arvinas Inc	13.49	$ 316.700 Millions	$ 23.475 Millions
Rosecliff Acquisition Corp I	13.43	$ 16.467 Millions	$ 1.226 Millions
Corcept Therapeutics Inc	13.30	$ 830.813 Millions	$ 62.477 Millions
Precipio inc	13.25	$ 27.198 Millions	$ 2.052 Millions

Date modified: 2026-09-03T21:08:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.